Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed press release in connection with the inclusion of certain brands in the global strategic alternatives review for Consumer Healthcare business. Please take the above on record. Announcement under Regulation 30 (LODR)-Updates
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Announcement under Regulation 30 (LODR)-Change in Directorate
This is to inform you that Mr. Ravi Prakash Bhagavathula has tendered his resignation as the Executive Director - Finance & Chief Financial Officer of Pfizer Limited to pursue opportunities outside Pfizer effective such date as may be agreed between Mr. Bhagavathula and the Board of Directors of the Company.
Glaxo, Reckitt are said only bidders for Pfizer's consumer unit
GlaxoSmithKline and Reckitt Benckiser are the only companies to have submitted non-binding bids for Pfizer's consumer business after rival candidates walked away
ICMR partners with Pfizer to combat antimicrobial resistance
The joint initiative will implement a series of comprehensive interventions, ranging from AMR stewardship programmes for nursing homes to scaling up of the ongoing AMR surveillance network Drug firm Pfizer Q3 net profit surges 40% to Rs 872 mn on lower expenses
The company had posted a net profit of Rs 623 million during the same period of the previous fiscal Press Release / Media Release
Please find enclosed press release for the financial results for the quarter and nine months ended December 31, 2017. Please take the above on record. Unaudited Financial Results For The Quarter Ended December 31, 2017.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and nine months ended December 31, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 12:30 p.m. and concluded at 2:00 p.m.... Board Meeting For The Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2017 And Intimation Of Closure Of Trading Window.
This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, January 24, 2018, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from January 16, 2018 to January 26, 2018, both days inclusive.... Shareholding for the Period Ended December 31, 2017
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here